ClinicalTrials.gg
CompletedNCT02352896Updated Oct 23, 2024

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

A Phase 2 interventional study of EPI-743 in Leigh Syndrome, sponsored by PTC Therapeutics. Completed at 4 sites in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jan 2014, registered Aug 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.

Started
2014
with 1 other
Phase 2
5 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
5 of 14
PTC Therapeutics

Among the 14 studies in Leigh Disease with a site in United States, this one is one of 2 that started in 2014, is one of 5 in phase 2, and was the 8th registered.

Leigh Disease

20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.

Browse Leigh Disease studies →

Open to participants now

6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leigh Disease with a site in United States, or all of them as a file.
02

Study summary

EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.

Read the detailed description

To monitor the long-term safety and neurodevelopmental effects of EPI-743 on children who complete the EPI743-12-002 placebo-controlled trial.

03

Conditions studied

  • Leigh Syndrome

Keywords

  • Leigh syndrome
  • Mitochondrial disorders
  • EPI743
  • Vincerinone
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Leigh syndrome with genetic confirmation
  2. Completion of EPI743-12-002 protocol and initiation of treatment within 14 days of Month 12 visit in EPI743-12-002 study
  3. Participant or participant's guardian able to consent and comply with protocol requirements
  4. Continued abstention from supplements excluded in EPI743-12-002 study
  5. Botox® is allowed if approved by the sponsor

Exclusion criteria

Exclusion Criteria:

  1. Allergy to EPI-743 or sesame oil
  2. Allergy to vitamin E
  3. Clinical history of bleeding or abnormal baseline (PT)/partial thromboplastin time (PTT)
  4. Hepatic insufficiency with liver function tests (LFTs) greater than two times
  5. Renal insufficiency requiring dialysis
  6. End-stage cardiac failure
  7. Fat malabsorption syndromes precluding drug absorption
  8. Use of anticoagulant medications
  9. Participation in other clinical research studies/taking other experimental agents
  10. Participation in elective procedures that required sedation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    EPI-743

    Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.

    Drug: EPI-743

Interventions

  • EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.

    Also known as: Vincerinone, Vatiquinone

06

What researchers measure

Primary outcomes

  1. Disease Severity as Measured by Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3 Score

    NPMDS is a validated scale to assess the mitochondrial disease progression.

    Time frame: Baseline up to Month 36

  2. Number of Participants With Dose-Limiting Serious Adverse Events (SAEs)

    Time frame: Baseline up to Month 36

Secondary outcomes

  1. Bayley Scales of Infant Development-III Score (Participants Age 0-3)

    Effect of EPI-743 on neurodevelopment will be measured by Bayley Scales of Infant Development-III score.

    Time frame: Baseline up to Month 24

  2. Wechsler Scale of Intelligence and Movement Assessment Battery Score for Children (Participants Age 4-18)

    Effect of EPI-743 on neuromuscular function will be assessed by Wechsler Scale of Intelligence and Movement Assessment Battery score.

    Time frame: Baseline up to Month 24

  3. Barry-Albright Dystonia Scale Score

    Neuromuscular function will be assessed by Barry-Albright Dystonia Scale score.

    Time frame: Baseline up to Month 24

  4. Gross Motor Function Measure

    Neuromuscular function will be assessed by gross motor function measure.

    Time frame: Baseline up to Month 24

  5. Awake Oxygen Saturation Levels

    Effect of EPI-743 on respiratory function will be measured by awake oxygen saturation levels.

    Time frame: Baseline up to Month 24

  6. Total Ventilator Days and Total Intensive Care Unit Days

    Time frame: Baseline up to Month 24

  7. Number of Participants With Pneumonia Episodes and Tracheostomy

    Time frame: Baseline up to Month 24

  8. Total Number of Mortalities, Medical Encounters, Hospitalizations, and Hospital Days

    Time frame: Baseline up to Month 24

  9. Health-Related Quality of Life as Measured by NPMDS Section 4 Score

    Time frame: Baseline up to Month 24

  10. Glutathione Cycle Biomarkers Level

    Time frame: Baseline up to Month 24

07

Study locations

4 sites
  • Gregory Enns
    Stanford University, California 94305, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Oct 2023, 116 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2014
First posted
Feb 2, 2015
StartActual
Jan 31, 2014
Primary completionActual
Oct 30, 2023
CompletionActual
Oct 30, 2023
Results delay requested
Oct 22, 2024
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02352896
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Feb 2, 2015
Start date
Jan 31, 2014
Primary completion
Oct 30, 2023
Completion
Oct 30, 2023
Last update
Oct 23, 2024

Study contacts

Bruce Cohen, MD
principal investigator · Akron Children's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion